Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting: Annals of oncology : official journal of the European Society for Medical Oncology

F. Amant, P. Berveiller, I.A. Boere, E. Cardonick, R. Fruscio, M. Fumagalli, M.J. Halaska, A. Hasenburg, A.L.V. Johansson, M. Lambertini, C.A.R. Lok, C. Maggen, P. Morice, F. Peccatori, P. Poortmans, K. Van Calsteren, T. Vandenbroucke, M. van Gerwen, M. van den Heuvel-Eibrink, F. ZagouriI. Zapardiel

Research output: Contribution to journalArticle

Abstract

We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health care providers. This allows further optimization of maternal treatment, while considering fetal development and providing psychological support and long-term follow-up of the infants. Nonionizing imaging procedures are preferred diagnostic procedures, but limited ionizing imaging methods can be allowed if indispensable for treatment plans. In contrast to other cancers, standard surgery for gynecological cancers often needs to be adapted according to cancer type and gestational age. Most standard regimens of chemotherapy can be administered after 14 weeks gestational age but are not recommended beyond 35 weeks. C-section is recommended for most cervical and vulvar cancers, whereas vaginal delivery is allowed in most ovarian cancers. Breast-feeding should be avoided with ongoing chemotherapeutic, endocrine or targeted treatment. More studies that focus on the long-term toxic effects of gynecologic cancer treatments are needed to provide a full understanding of their fetal impact. In particular, data on targeted therapies that are becoming standard of care in certain gynecological malignancies is still limited. Furthermore, more studies aimed at the definition of the exact prognosis of patients after antenatal cancer treatment are warranted. Participation in existing registries (www.cancerinpregnancy.org) and the creation of national tumor boards with multidisciplinary teams of care providers (supplementary Box S1, available at Annals of Oncology online) is encouraged. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Original languageEnglish
Pages (from-to)1601-1612
Number of pages12
JournalAnn. Oncol.
Volume30
Issue number10
DOIs
Publication statusPublished - 2019

Fingerprint

Consensus
Guidelines
Pregnancy
Neoplasms
Therapeutics
Gestational Age
Vulvar Neoplasms
Gynecologic Surgical Procedures
Manuscripts
Poisons
Standard of Care
Fetal Development
Breast Feeding
Uterine Cervical Neoplasms
Health Personnel
Ovarian Neoplasms
Infertility
Registries
Pregnant Women
Mothers

Keywords

  • cancer
  • chemotherapy
  • cognitive
  • gynecologic
  • offspring
  • pregnancy

Cite this

Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting : Annals of oncology : official journal of the European Society for Medical Oncology. / Amant, F.; Berveiller, P.; Boere, I.A.; Cardonick, E.; Fruscio, R.; Fumagalli, M.; Halaska, M.J.; Hasenburg, A.; Johansson, A.L.V.; Lambertini, M.; Lok, C.A.R.; Maggen, C.; Morice, P.; Peccatori, F.; Poortmans, P.; Van Calsteren, K.; Vandenbroucke, T.; van Gerwen, M.; van den Heuvel-Eibrink, M.; Zagouri, F.; Zapardiel, I.

In: Ann. Oncol., Vol. 30, No. 10, 2019, p. 1601-1612.

Research output: Contribution to journalArticle

Amant, F, Berveiller, P, Boere, IA, Cardonick, E, Fruscio, R, Fumagalli, M, Halaska, MJ, Hasenburg, A, Johansson, ALV, Lambertini, M, Lok, CAR, Maggen, C, Morice, P, Peccatori, F, Poortmans, P, Van Calsteren, K, Vandenbroucke, T, van Gerwen, M, van den Heuvel-Eibrink, M, Zagouri, F & Zapardiel, I 2019, 'Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting: Annals of oncology : official journal of the European Society for Medical Oncology', Ann. Oncol., vol. 30, no. 10, pp. 1601-1612. https://doi.org/10.1093/annonc/mdz228
Amant, F. ; Berveiller, P. ; Boere, I.A. ; Cardonick, E. ; Fruscio, R. ; Fumagalli, M. ; Halaska, M.J. ; Hasenburg, A. ; Johansson, A.L.V. ; Lambertini, M. ; Lok, C.A.R. ; Maggen, C. ; Morice, P. ; Peccatori, F. ; Poortmans, P. ; Van Calsteren, K. ; Vandenbroucke, T. ; van Gerwen, M. ; van den Heuvel-Eibrink, M. ; Zagouri, F. ; Zapardiel, I. / Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting : Annals of oncology : official journal of the European Society for Medical Oncology. In: Ann. Oncol. 2019 ; Vol. 30, No. 10. pp. 1601-1612.
@article{3ee3e7f0cbc64a20ac26bed489411856,
title = "Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting: Annals of oncology : official journal of the European Society for Medical Oncology",
abstract = "We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health care providers. This allows further optimization of maternal treatment, while considering fetal development and providing psychological support and long-term follow-up of the infants. Nonionizing imaging procedures are preferred diagnostic procedures, but limited ionizing imaging methods can be allowed if indispensable for treatment plans. In contrast to other cancers, standard surgery for gynecological cancers often needs to be adapted according to cancer type and gestational age. Most standard regimens of chemotherapy can be administered after 14 weeks gestational age but are not recommended beyond 35 weeks. C-section is recommended for most cervical and vulvar cancers, whereas vaginal delivery is allowed in most ovarian cancers. Breast-feeding should be avoided with ongoing chemotherapeutic, endocrine or targeted treatment. More studies that focus on the long-term toxic effects of gynecologic cancer treatments are needed to provide a full understanding of their fetal impact. In particular, data on targeted therapies that are becoming standard of care in certain gynecological malignancies is still limited. Furthermore, more studies aimed at the definition of the exact prognosis of patients after antenatal cancer treatment are warranted. Participation in existing registries (www.cancerinpregnancy.org) and the creation of national tumor boards with multidisciplinary teams of care providers (supplementary Box S1, available at Annals of Oncology online) is encouraged. {\circledC} The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
keywords = "cancer, chemotherapy, cognitive, gynecologic, offspring, pregnancy",
author = "F. Amant and P. Berveiller and I.A. Boere and E. Cardonick and R. Fruscio and M. Fumagalli and M.J. Halaska and A. Hasenburg and A.L.V. Johansson and M. Lambertini and C.A.R. Lok and C. Maggen and P. Morice and F. Peccatori and P. Poortmans and {Van Calsteren}, K. and T. Vandenbroucke and {van Gerwen}, M. and {van den Heuvel-Eibrink}, M. and F. Zagouri and I. Zapardiel",
note = "Cited By :1 Export Date: 25 November 2019",
year = "2019",
doi = "10.1093/annonc/mdz228",
language = "English",
volume = "30",
pages = "1601--1612",
journal = "Ann. Oncol.",
issn = "1569-8041",
publisher = "NLM (Medline)",
number = "10",

}

TY - JOUR

T1 - Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting

T2 - Annals of oncology : official journal of the European Society for Medical Oncology

AU - Amant, F.

AU - Berveiller, P.

AU - Boere, I.A.

AU - Cardonick, E.

AU - Fruscio, R.

AU - Fumagalli, M.

AU - Halaska, M.J.

AU - Hasenburg, A.

AU - Johansson, A.L.V.

AU - Lambertini, M.

AU - Lok, C.A.R.

AU - Maggen, C.

AU - Morice, P.

AU - Peccatori, F.

AU - Poortmans, P.

AU - Van Calsteren, K.

AU - Vandenbroucke, T.

AU - van Gerwen, M.

AU - van den Heuvel-Eibrink, M.

AU - Zagouri, F.

AU - Zapardiel, I.

N1 - Cited By :1 Export Date: 25 November 2019

PY - 2019

Y1 - 2019

N2 - We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health care providers. This allows further optimization of maternal treatment, while considering fetal development and providing psychological support and long-term follow-up of the infants. Nonionizing imaging procedures are preferred diagnostic procedures, but limited ionizing imaging methods can be allowed if indispensable for treatment plans. In contrast to other cancers, standard surgery for gynecological cancers often needs to be adapted according to cancer type and gestational age. Most standard regimens of chemotherapy can be administered after 14 weeks gestational age but are not recommended beyond 35 weeks. C-section is recommended for most cervical and vulvar cancers, whereas vaginal delivery is allowed in most ovarian cancers. Breast-feeding should be avoided with ongoing chemotherapeutic, endocrine or targeted treatment. More studies that focus on the long-term toxic effects of gynecologic cancer treatments are needed to provide a full understanding of their fetal impact. In particular, data on targeted therapies that are becoming standard of care in certain gynecological malignancies is still limited. Furthermore, more studies aimed at the definition of the exact prognosis of patients after antenatal cancer treatment are warranted. Participation in existing registries (www.cancerinpregnancy.org) and the creation of national tumor boards with multidisciplinary teams of care providers (supplementary Box S1, available at Annals of Oncology online) is encouraged. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

AB - We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health care providers. This allows further optimization of maternal treatment, while considering fetal development and providing psychological support and long-term follow-up of the infants. Nonionizing imaging procedures are preferred diagnostic procedures, but limited ionizing imaging methods can be allowed if indispensable for treatment plans. In contrast to other cancers, standard surgery for gynecological cancers often needs to be adapted according to cancer type and gestational age. Most standard regimens of chemotherapy can be administered after 14 weeks gestational age but are not recommended beyond 35 weeks. C-section is recommended for most cervical and vulvar cancers, whereas vaginal delivery is allowed in most ovarian cancers. Breast-feeding should be avoided with ongoing chemotherapeutic, endocrine or targeted treatment. More studies that focus on the long-term toxic effects of gynecologic cancer treatments are needed to provide a full understanding of their fetal impact. In particular, data on targeted therapies that are becoming standard of care in certain gynecological malignancies is still limited. Furthermore, more studies aimed at the definition of the exact prognosis of patients after antenatal cancer treatment are warranted. Participation in existing registries (www.cancerinpregnancy.org) and the creation of national tumor boards with multidisciplinary teams of care providers (supplementary Box S1, available at Annals of Oncology online) is encouraged. © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

KW - cancer

KW - chemotherapy

KW - cognitive

KW - gynecologic

KW - offspring

KW - pregnancy

U2 - 10.1093/annonc/mdz228

DO - 10.1093/annonc/mdz228

M3 - Article

VL - 30

SP - 1601

EP - 1612

JO - Ann. Oncol.

JF - Ann. Oncol.

SN - 1569-8041

IS - 10

ER -